Tinengotinib in patients with advanced, metastatic cholangiocarcinoma: Overall survival results and biomarker correlative analysis from a phase 2 clinical trial.

被引：0
|
作者：
Fountzilas, Christos
Liao, Chih-Yi
Pelster, Meredith
Li, Daneng
Deming, Dustin A.
Sahai, Vaibhav
Kankeu Fonkoua, Lionel Aurelien
Cohn, Allen Lee
Mantry, Parvez
Richards, Donald A.
Kingsley, Ed
Wu, Frank
Peng, Peng
Hennessy, Katie
Wang, Hui
Shan, Yujun
Sun, Caixia
Fan, Jean
Javle, Milind M.
Mahipal, Amit
机构：
[1] Roswell Pk Comprehens Canc Ctr, Buffalo, NY USA
[2] Univ Chicago, Med Ctr, Chicago, IL USA
[3] Sarah Cannon Res Inst, Nashville, TN USA
[4] City Hope Natl Comprehens Canc Ctr, Duarte, CA USA
[5] Univ Wisconsin, Carbone Canc Ctr, Madison, WI USA
[6] Univ Michigan, Ann Arbor, MI USA
[7] Mayo Clin Rochester, Dept Med Oncol, Rochester, MN USA
[8] Rocky Mt Canc Ctr, Denver, CO USA
[9] Liver Inst Methodist Dallas, Dallas, TX USA
[10] Texas Oncol Tyler, Tyler, TX USA
[11] Comprehens Canc Ctr Nevada, Las Vegas, NV USA
[12] TransThera Sci Nanjing Inc, Nanjing, Peoples R China
[13] TransThera Sci US Inc, Gaithersburg, MD USA
[14] Univ Texas MD Anderson Canc Ctr, Dept Gastrointestinal Med Oncol, Houston, TX USA
[15] Case Western Reserve Univ, Univ Hosp Seidman Canc Ctr, Cleveland Hts, OH USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2025年 / 43卷 / 4_SUPPL期
关键词：
D O I：
10.1200/JCO.2025.43.4_suppl.608
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
608
引用
收藏
页码：608 / 608
页数：1
相关论文
共 50 条
  • [41] Efficacy of nivolumab and temozolomide in advanced neuroendocrine neoplasms (NENs) in a phase 2 clinical trial.
    Owen, Dwight Hall
    Benner, Brooke
    Wei, Lai
    Sukrithan, Vineeth
    Goyal, Ashima
    Zhou, Ye
    Suffren, Sheryl-Ann
    Pilcher, Carly
    Christenson, Gwen
    Curtis, Nancy
    Savardekar, Himanshu
    Norman, Ruthann
    Ferguson, Sarah
    Kleiber, Barbara
    Wesolowski, Robert
    Carson, William Edgar
    Otterson, Gregory Alan
    Verschraegen, Claire F.
    Shah, Manisha H.
    Konda, Bhavana
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [42] Biomarker Testing and Overall Survival among Patients Diagnosed with Advanced or Metastatic Non-small Cell Lung Cancer
    Hess, L.
    Beyrer, J.
    Abedtash, H.
    JOURNAL OF MOLECULAR DIAGNOSTICS, 2020, 22 (11): : S79 - S79
  • [43] Overall survival (OS) and efficacy results of second-line treatment in patients (pts) with metastatic clear cell renal cell carcinoma (mRCC) treated in the randomized phase II BIONIKK trial.
    Vano, Yann-Alexandre
    Phan, Letuan
    Simonaggio, Audrey
    Bennamoun, Mostefa
    Pannier, Diane
    Chevreau, Christine
    Borchiellini, Delphine
    Maillet, Denis
    Gross-Goupil, Marine
    Laguerre, Brigitte
    Tournigand, Christophe
    Barthelemy, Philippe
    Coquan, Elodie
    Gravis, Gwenaelle
    Sun, Cheng-Ming
    Meylan, Maxime
    Fridman, Wolf-Herve
    Sautes-Fridman, Catherine
    Elaidi, Reza
    Oudard, Stephane
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41
  • [44] Development and validation of a prognostic model for overall survival in chemotherapy-naive men with metastatic castration-resistant prostate cancer (mCRPC) from the phase 3 prevail clinical trial.
    Armstrong, Andrew J.
    Lin, Ping
    Higano, Celestia S.
    Sternberg, Cora N.
    Sonpavde, Guru
    Tombal, Bertrand F.
    Templeton, Arnoud J.
    Fizazi, Karim
    Phung, De
    Wong, Elaine K.
    Krivoshik, Andrew
    Beer, Tomasz M.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [45] Development and validation of a prognostic model for overall survival in chemotherapy-naive men with metastatic castration-resistant prostate cancer (mCRPC) from the phase III PREVAIL clinical trial.
    Armstrong, Andrew J.
    Lin, Ping
    Higano, Celestia S.
    Sternberg, Cora N.
    Sonpavde, Guru
    Tombal, Bertrand F.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (06)
  • [46] Overall survival (OS) and biomarker results from combat: A phase 2 study of bipolar androgen therapy (BAT) plus nivolumab for patients with metastatic castrate-resistant prostate cancer (mCRPC).
    不详
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [47] Bortezomib in PTEN-deficient patients with advanced intrahepatic cholangiocarcinoma: An open-label, prospective, phase II trial.
    Yuan, Zhen-Gang
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [48] Hepatic arterial infusion pump chemotherapy in patients with advanced intrahepatic cholangiocarcinoma confined to the liver: A multicenter phase II trial.
    Franssen, Stijn
    Rousian, Merve
    Nooijen, Lynn E.
    ten Haaft, Britte H. E. A.
    Doukas, Michael
    Mohammad, Nadia Haj
    Klumpen, Heinz-Josef
    Moelker, Adriaan
    Mostert, Bianca
    Hagendoorn, Jeroen
    Swijnenburg, Rutger-Jan
    Homs, Marjolein Y. V.
    Koerkamp, Bas Groot
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (3_SUPPL) : 433 - 433
  • [49] Phase III clinical study results offer new hope for improved survival rates in patients with advanced metastatic melanoma
    不详
    PHARMACOGENOMICS, 2011, 12 (03) : 304 - 304
  • [50] Analysis of liquid biopsies from metastatic colorectal carcinoma (mCRC) patients (pts) enrolled in the ERMES clinical trial.
    Normanno, Nicola
    Barone, Carlo
    Maiello, Evaristo
    Di Costanzo, Francesco
    Cassata, Antonio
    Tamburini, Emiliano
    Tonini, Giuseppe
    Bordonaro, Roberto
    Rosati, Gerardo
    Zaniboni, Alberto
    Lonardi, Sara
    Ferrari, Daris
    Frassineti, Giovanni Luca
    Tamberi, Stefano
    Pisconti, Salvatore
    Di Fabio, Francesca
    Forgione, Laura
    Rachiglio, Anna Maria
    Pasquale, Raffaella
    Pinto, Carmine
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
12345